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doi:10.1016/j.ejvs.2008.04.001Abstract Carotid endarterectomy (CEA) for carotid stenosis is effective in preventing ipsilat-
eral carotid territory ischaemic stroke. Paradoxically however, it causes a stroke (the event it
is trying to prevent) in about 5% or more of cases. If carotid angioplasty/stenting (CAS) is to
have a place in the management of patients with carotid stenosis (beyond those who are
not suitable for CEA), it has to demonstrate that it is also effective and safe.
Limited data from 12 randomised trials comparing CAS with CEA (the current ‘‘gold
standard’’) in a total of 3227 patients with carotid stenosis (90% symptomatic) question the
safety of CAS and suggest that it may cause more non-fatal, procedural strokes than CEA de-
spite similar mortality rates and a much lower immediate local complication rate (eg cranial
neuropathy). However, the published trials are rather heterogeneous (clinically and methodo-
logically), none is large enough to provide robust and convincing data and long-term follow-up
is very limited. Accordingly, it remains unknown whether CAS is effective in preventing
recurrent stroke among patients with carotid stenosis, or whether it is safe.
More data (from at least another 3,000 patients) are needed from the ongoing randomised
trials before it can reliably be concluded whether CAS is inferior to, non-inferior to, or more
effective than, CEA. More importantly, it will be possible to determine which patients should
be treated preferentially with CAS, which patients with CEA, and which patients should not
undergo either revascularisation procedure.
Crown Copyright ª 2008 Published by Elsevier Ltd on behalf of European Society for Vascular
Surgery. All rights reserved.Prof. A. Ross Naylor, Leices-
t, Royal Perth Hospital, 197
lia.
.uwa.edu.au
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Randomised controlled trials performed over the last two
decades have shown that the addition of CEA to best
medical therapy is beneficial in reducing the absolute riskehalf of European Society for Vascular Surgery. All rights reserved.
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(95% CI: 10e21%) for patients with severe (70e99%) symp-
tomatic carotid stenosis,1 8% (95% CI: 3e12%) for patients
with moderate (50e69%) symptomatic carotid stenosis,1
and 5% for patients with neurologically asymptomatic se-
vere (60e99%) carotid stenosis.2 Moreover, the durability
of CEA in preventing ipsilateral carotid territory ischaemic
stroke has been proven over as long a time period as 13
years.3 However, it is important to remain aware that there
are also important limitations to CEA (Table 1).
CAS is an Attractive Alternative Procedure
to CEA
Endovascular techniques for treating carotid stenosis have
emerged over recent years to prevent ipsilateral carotid
territory ischaemic stroke. Theoretically, however, CAS
may not be found to be effective because most ischaemic
carotid territory strokes follow embolism of thrombus from
a carotid plaque to the brain or eye. Unlike the coronary
circulation, for which coronary stenting may immediately
relieve angina, carotid stenosis rarely causes a stroke due
to low-flow (i.e. haemodynamic compromise) and it only
does so if the underlying stenosis is very severe (>95%) and
the collateral blood supply (e.g. via the Circle of Willis) is
inadequate. The potential advantages and disadvantages of
CAS are listed in Table 2.
What is the Evidence from Randomised
Trial Comparing the Safety and Efficacy
of CAS with CEA?
Systematic reviews and meta-analyses
It is appropriate to begin by reviewing the totality of
evidence from all randomised controlled trials. This re-
quires a systematic review of all trials and a meta-analysis
of data from all trials.Table 1 Limitations of carotid endarterectomy
1. Less suitable for patients with surgically inaccessible
extracranial carotid artery disease (e.g. high carotid
bifurcation), restenosis after previous carotid
endarterectomy and previous local radiation exposure;
2. Requires admission to hospital for two days4;
3. Requires a general anaesthetic for some patients
(increasing the potential risk of myocardial infarction
and venous thromboembolism);
4. Requires an incision in the neck;
5. Causes a scar on the neck, and may be responsible for
cutaneous or cranial nerve injuries and wound
haematoma which can become infected or compress
vital neck structures;
6. Paradoxically, CEA may cause a stroke, usually as a
result of carotid thromboembolism; the 30 day rate of
stroke or death is about 8.4% for patients with moderate
(50e69%), and 6.2% for patients with severe (70e99%),
symptomatic carotid stenosis1;
7. Costs about US $12,000 (total procedural costs).4,5A systematic review uses explicit scientific strategies to
a) identify and include all trials that are relevant to the
research question, b) reduce any bias (e.g. in trial selection
and data extraction) in the estimate of the direction of the
treatment effect (of carotid stenting vs endarterectomy)
from using only selected trials, and c) increase the preci-
sion of the estimate of the treatment effect by examining
a larger amount of data and thereby reducing random
error.7
A meta-analysis is commonly performed using the in-
verse variance method in which the weight given to each
study is the inverse of the variance of the effect estimate
(i.e. one divided by the square of its standard error).
Thus larger studies, which have smaller standard errors,
are given more weight than smaller studies, which have
larger standard errors. This choice of weight minimizes
the imprecision (uncertainty) of the pooled effect esti-
mate.7 A fixed-effect meta-analysis makes the assumption
that the true effect of the intervention (e.g. CAS vs CEA),
in both direction and magnitude, is the same value in every
study (that is, it is fixed across studies). This assumption
implies that any observed differences among study results
are due solely to the play of chance, i.e. that there is no
statistical heterogeneity.
However, observed differences among study results may
also reflect heterogeneity resulting from clinical and/or
methodological diversity among the trials. Heterogeneity is
assessed using a Cochran Q statistic, and P-value obtained
by comparing the Q statistic with a c2 distribution with
k1 degrees of freedom, where k is the number of studies.
Heterogeneity is also assessed using the I2 statistic, which
describes the percentage of variation across studies that
is due to heterogeneity (rather than chance) and is calcu-
lated as 100% (Q df)/Q where Q is the Cochran Q
statistic.7,8 I2 is an intuitive and simple expression of the
inconsistency of studies’ results because, unlike Q, it
does not inherently depend on the number of studies
considered.
If there is heterogeneity and this cannot be readily
explained, one approach is to incorporate the data into
a random-effects meta-analysis model. This involves the
assumption that the effects being estimated in the differ-
ent studies are not identical (i.e. fixed), but follow some
sort of distribution. The random effects model represents
our lack of knowledge about why the observed effects of
the intervention differ by considering the differences as if
they were random. The centre of this distribution describes
the average of the effects, while its width describes the
degree of heterogeneity. The conventional choice of distri-
bution is a normal distribution. As it is difficult to establish
the validity of any distributional assumption, random-
effects meta-analyses are open to criticism.
If the variation in the results of different studies
(heterogeneity) is due to biases associated with methodo-
logical diversity, the random-effects pooled estimate will
only estimate the average treatment effect provided the
biases are symmetrically distributed, leading to a mixture
of over- and under-estimates of effect. However, this is
unlikely to be the case. If the variation in effects (hetero-
geneity) is due to clinical diversity, the fixed-effect pooled
estimate should be interpreted differently from the ran-
dom-effects estimate since it relates to a completely
Table 2 Advantages and disadvantages of carotid angioplasty/stenting
Advantages
1. Access to, and treatment of, surgically inaccessible carotid lesions in the neck;
2. Less invasive
a. General anaesthetic is not required;
b. Incision in the neck is not required;
3. Quicker
a. Hospital admission time usually one day (cf. endarterectomy: two days).4
Disadvantages
1. Not suitable if there is a contrast allergy, severe aortic arch atheroma, highly tortuous arteries or lumen thrombus;
2. Femoral artery puncture is required, which may cause a cutaneous or femoral nerve injury, and a wound haematoma which may
become infected or compress vital groin structures;
3. Higher total procedural costs (US $17,400 for carotid stenting vs $12,100 for endarterectomy, pZ 0.034), due to more expensive
devices used for endovascular treatment).
4. Paradoxically, it may cause a stroke, as a result of arterial dissection, late embolisation of thrombus on damaged plaque, hypoten-
sion (carotid sinus stimulation), aneurysm formation, or arterial puncture. The recently published multicentre Carotid Acculink/
Accunet Post-Approval Trial to Uncover Unanticipated or Rare Events (CAPTURE) registry reported that among 3,500 patients with
carotid stenosis and high surgical risk who underwent carotid stenting with embolic protection by 353 physicians at 144 sites in the
post approval setting, the risk of suffering the composite endpoint of stroke, myocardial infarction or death within 30 days of
stenting was 6.3% (5.4% among the 3,018 neurologically asymptomatic patients with 12.0% among the 482 symptomatic patients).6
5. Uncertain durability over many years in preventing ipsilateral carotid ischaemic stroke.
6. Uncertain safety and efficacy compared with the ‘‘gold standard’’ of carotid endarterectomy.
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fidence interval addresses the question ‘‘what is the best
estimate of the intervention effect?’’ The random-effects
estimate and its confidence interval address the question
‘‘what is the average intervention effect?’’ The answers
to these questions coincide either when no heterogeneity
is present, or when the distribution of the intervention
effects is roughly symmetrical. When the answers do not
coincide, the random-effects estimate may not reflect
the actual effect in any particular population being
studied.
In this paper I will examine a recently updated Cochrane
systematic review and meta-analysis of all randomised
trials comparing CAS with CEA.9 This will provide an esti-
mate of the overall treatment effect of stenting vs endar-
terectomy as well as an analysis of whether there is
consistency or heterogeneity of the treatment effect
among the different trials. If there is consistency, the
next question to be addressed is whether there is sufficient
statistical power to perform hypothesis-generating sub-
group analyses, acknowledging the potential hazards of
this type of analysis.7 However, if there is highly significant
heterogeneity, the validity of combining the data (e.g. for
a meta-analysis) may be doubtful. The validity of the
systematic review and meta-analysis will also be limited if
there is any bias. Examples of this include publication
bias [studies which have concluded a ‘‘positive’’ or inter-
esting result are more likely to be published, and therefore
easier to locate, than studies which have produced
a ‘‘negative’’ or neutral result], study quality bias [more
methodologically robust trials tend to indicate that new
treatments are less effective than do less reliable trials]
and outcome recording bias [where there is a tendency
for some trials to publish the results of their most impres-
sive outcomes and not report the results of their least
impressive outcomes]).7Cochrane systematic review and meta-analysis of
all available data from randomised trials
The recent Cochrane systematic review9 identified 12
randomised trials that compared the safety and efficacy
of endovascular treatment of carotid stenosis by means of
percutaneous transluminal carotid angioplasty and/or
stenting with CEA in a total of 3,227 patients.10e21 Five
trials, involving 2,286 patients, were stopped early.11e15
Five clinically relevant questions will be addressed
(Table 3):
1. Is CAS associated with a lower risk of procedural death
or stroke than CEA?
Eight trials involving 2,915 patients with carotid steno-
sis (about 90% symptomatic) reported the major outcome
of ‘‘any stroke or death within 30 days of the proce-
dure’’.10e17 A meta-analysis of the available data showed
no significant heterogeneity among the eight trials (c2
11.81, PZ 0.11, I2Z 41%) and a significant excess risk of
death/stroke among patients randomly assigned CAS,
compared with CEA (122/1464 [8.3%] stenting vs 89/1451
[6.1%] endarterectomy; fixed-effect odds ratio [OR]:
1.39, 95% confidence interval [CI]: 1.05 to 1.84, PZ 0.02).
This result may be viewed as a typical intervention
effect from the studies included in the analysis and
suggests a significant increase in the odds of procedural
stroke or death among patients treated with CAS compared
with CEA. However, the estimate of excess risk (about 39%)
is imprecise and varies, with 95% confidence limits from as
low as 5% to as high as 84%. When the random-effects model
was used, the pooled estimate and confidence interval of
the odds ratio for 30-day death/stroke among patients
assigned to CAS compared with CEA was similar (OR: 1.44).
However, the 95% confidence intervals were now even
Table 3 Questions addressed in the trials of CAS vs CEA
1. Is CAS associated with a lower risk of periprocedural death or stroke CEA?
Preliminary evidence suggests that CAS and CEA incur a similar perioperative mortality rate (1.2%), but that CAS may have about
a 40% (5 to 84%) higher relative risk and 2% higher absolute risk of 30-day stroke compared with CEA.
2. Does CAS incur fewer local periprocedural complications than CEA?
CAS significantly reduces the relative risk of cranial nerve injury by 90% and by about 7% in absolute terms (7.2% endarterectomy
vs 0.4% angioplasty/stent).
3. Is CAS as effective as CEA in reducing long-term stroke?
Limited long-term follow-up data suggest that there was no significant difference between the treatments in preventing stroke or
death, but the confidence intervals are wide and there is significant heterogeneity among the trials.
4. Is CAS with a cerebral protection device more effective than CAS without cerebral protection?
Preliminary case series have suggested that protection devices do improve the safety of stenting, but there are no reliable
data from trials in which patients were randomly assigned to the use of cerebral protection devices or not.
5. Is CAS as effective as CEA in reducing the 30-day risk of death/stroke in neurologically asymptomatic carotid stenosis?
There are insufficient data from trials in which patients with neurologically asymptomatic carotid stenosis were randomly
assigned to CAS vs CEA.
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indicating that the result was not statistically significant at
the pZ 0.05 level.
It is important to note that the increased risk of 30-day
death/stroke after CAS was not driven by an excess risk of
death. Among the seven trials which recorded death within
30 days of the procedure10e12,14e17 (2,683 patients), there
was no significant heterogeneity among the trials
(pZ 0.69; I2Z 0%) and no significant difference between
treatment groups (30-day death 16/1352 [1.2%] following
stenting vs 16/1331 [1.2%] after endarterectomy). This
corresponds to a fixed-effect OR 0.99 (95% CI: 0.50e1.97,
PZ 0.98) and a random-effects OR 1.00 (95% CI 0.49e
2.04, PZ 0.99). The identical results achieved by both
the fixed-effect and random-effects methods (albeit with
wide 95% confidence intervals and thus substantial impreci-
sion of the estimates) suggest that there was no heteroge-
neity among the various studies for procedural death.
Accordingly, the observed increase in procedural risk after
CAS was driven by an increase in the odds of stroke (97/
1357 [7.1%] after stenting vs 70/1341 [5.2%] after endarter-
ectomy. Fixed-effect ORZ 1.40 (95% CI 1.02e1.91,
PZ 0.04). There was substantial heterogeneity among the
seven trials (c2 10.65, PZ 0.06; I2Z 53%). The results
from the individual larger trials varied from favouring stent-
ing (SAPPHIRE14), equivalence (CAVATAS16 and SPACE15) to
favouring endarterectomy (EVA-3S).11 However, the cause
of the heterogeneity among the trials could not be ade-
quately determined because insufficient individual patient
data were available for the systematic review and meta-
analysis, and there were too few trials to justify further
subgroup analyses.
At first sight, it seems intuitive that the use of less
sophisticated angioplasty/stenting techniques by inexperi-
enced operators in trials comparing CAS with CEA might
explain the higher rates of procedural stroke associated
with angioplasty/stenting in the Leicester trial (OR 21.2;
95% CI: 1.01 to 445)12 and the EVA-3S trial (OR 3.5, 95% CI:
1.5 to 8.2),11 and therefore account for a substantial por-
tion of the heterogeneity of treatment effects seen in the
meta-analysis. However, there is no actual evidence to sup-
port this.9
First, a plot showing the stroke and death rate for each
of the trials in the systematic review over time revealed noimprovement in the 30-day event rate from trial to trial
with time.9 Second, an extensive analysis of the various
explanations for the higher risk of stroke among patients
assigned to CAS in the EVA-3S trial (8.7%) failed to reveal
any clear explanation regarding experience of the opera-
tors, baseline patient characteristics, centre enrolment or
other obvious factors other than the intrinsic nature of
the procedure. Paradoxically, the results for individual in-
vestigators in the EVA-3S study showed an inverse learning
curve (ie higher rates of procedural stroke/death among
more experienced operators).22 Interestingly, the main
finding (for many) from the EVA-3S trial was that the risk
of stroke among patients assigned to CEA was unusually
low compared with outcomes from all of the other trials
(2.7%), rather than the stroke rate being exceptionally
high among patients assigned to CAS.11 Finally, the CAP-
TURE registry found that the rate of stroke, myocardial
infarction or death within 30 days of stenting did not differ
amongst three operator experience levels.6
Other potential biases in the comparison of CAS with CEA,
which may have contributed to some of the heterogeneity of
results observed among the trials, were important differ-
ences in (i) the baseline characteristics of the study pop-
ulation, (ii) the revascularisation technique among the trials
and (iii) the duration of follow-up (Table 4).
The baseline characteristics of the randomised patients
were not the same in all of the trials. Although most only
included patients with neurologically symptomatic carotid
stenoses, two included patients with neurologically asymp-
tomatic carotid disease (70% of patients assigned to CAS in
the SAPPHIRE trial14 and 12% assigned to CAS in the CAVATAS
trial16 described no symptoms ipsilateral to the carotid
artery stenosis within six months of randomisation). The
SAPPHIRE trial also only recruited patients deemed ‘‘high
surgical risk’’.14 Although the CAVATAS protocol did not
specify ‘high risk’ as an exclusion criterion, a subsequent
analysis of the baseline characteristics suggested that
CAVATAS also selected a higher proportion of patients at
‘‘high surgical risk’’ compared to earlier trials of CEA.1,16
The revascularisation technique for performing CAS also
differed among the trials. In the earliest studies,10,12,13,16,19
most patients assigned to endovascular therapy were
treated with balloon angioplasty only and without cerebral
protection (which had not been invented). For example, in
Table 4 Differences among the trials comparing carotid angioplasty/stenting with endarterectomy
Patients
 Although most trials only included patients with neurologically symptomatic carotid stenosis, some included patients with
neurologically asymptomatic carotid stenosis.14,16
 Only patients at high surgical risk for carotid endarterectomy were included in the SAPPHIRE trial.14
Diagnosis
 Diagnostic angiography was mandatory before randomisation in three trials (and its risk was added to the treatment) whereas
patients could be randomised according to the results of non-invasive techniques (mainly duplex ultrasound) in other trials
Revascularisation technique
 The technique for carotid angioplasty/stenting has changed over time.
 Use of an embolus protection device (EPD) was varied among trials11,14,15
Operator experience
 Operator experience was different among the trials.10e21
Follow-up
 Data for death or any stroke during follow up were available from six trials, but events were given for different time points;
two trials presented results at six months’ after randomisation,11,20 two trials presented outcome events at 12 months after
randomisation,13,14 and one trial each presented results at two years17 and three years16 of follow up.
38 Graeme J. Hankeythe CAVATAS study,16 only 22% of patients underwent
stenting, usually following unsuccessful balloon dilatation.
Moreover, the stents were not designed for dedicated use
in the carotid artery. In subsequent trials,11,14,15 most
patients assigned to CAS received self-expanding thermal
stents in conjunction with the use of one of the various
cerebral protection devices.
Heterogeneity may also have arisen because the sys-
tematic review and meta-analysis included trials that had
been prematurely terminated11e15 in addition to those that
completed.10,16e21 These ‘‘early stopping trials’’, particu-
larly if the termination was data-dependent due to an
increased hazard, are at risk of over-estimating the risk
of the treatment.
The random-effects model for 30-day stroke produced
a similar odds ratio (OR: 1.47) to the fixed-effects model,
but the 95% confidence intervals were now wider (95% CI
0.81e2.67) and overlapped with an ORZ 1 (i.e. not statis-
tically significant at the pZ 0.05 level).9 This pooled esti-
mate and its confidence interval from the random-effects
meta-analysis refers to the centre of the distribution of
the effects of carotid stenting compared with endarterec-
tomy. The confidence interval describes uncertainty in
the location of the average of the systematically different
effects in the different studies. It does not describe the
width of the distribution. It also does not describe the de-
gree of heterogeneity among studies as may be commonly
believed. These findings from the random-effects model re-
duce the overall impact of the findings of the fixed-effect
model and suggest that the data may not be robust or reli-
able. Furthermore, the results may be biased because three
of the trials were stopped early because of an excess event
rate in the endovascular treatment group. Finally, the re-
sults may not be externally valid (ie generalisable) beyond
the centres which took part in the constituent trials (and
who had a specific interest in carotid intervention and sec-
ondary prevention of stroke).
2. Does CAS incur fewer local procedural complications
than CEA?
The rate of cranial nerve injury (CNI) within 30 days of
the procedure was reported in six trials. There was nosignificant heterogeneity among the studies (chi squared
1.87, PZ 0.60; I2Z 0%). There was, however, a significant
reduction in the rate of CNI in patients treated by CAS
(3/758 [0.4%] after stenting vs 54/755 [7.2%] after endar-
terectomy; fixed-effect OR: 0.07, 95% CI: 0.03 to 0.20,
random-effects OR: 0.09, 95% CI: 0.04 to 0.25).
3. Is CAS as effective as CEA in reducing long-term stroke?
Data for death/any stroke during follow up (including
the initial 30-day post-treatment phase) are available from
six trials, but (unfortunately) events are given for differing
time points. Two trials reported six months’ results,11,20
two presented outcome events at 12 months after random-
isation13,14 and one trial each presented results after two
years17 and three years16 of follow up. There was significant
heterogeneity among the trials (chi squared 14.05,
PZ 0.02; I2Z 64%). Overall, there was no significant differ-
ence in the rate of late death/stroke (81/882 [9.2%] after
stenting vs 73/888 [8.2%] after endarterectomy; fixed-
effect OR 1.13, 95% CI: 0.81 to 1.58). The random-effects
OR was 1.18 (95% CI: 0.61 to 2.28).
Data for the risk of suffering ‘any stroke’ during follow
up (excluding the initial 30-day post-treatment phase) were
available from three trials.11,14,17 Heterogeneity among tri-
als was not significant (chi squared 0.82, PZ 0.36; I2Z 0%).
The risk of late ‘any’ stroke was similar (14/441 [3.2%] after
stenting vs 14/439 [3.2%] after endarterectomy; fixed-
effect OR 1.00, 95% CI: 0.47 to 2.14, random-effects OR
0.99, 95% CI: 0.46 to 2.14).
4. Is CAS with a cerebral protection device more effective
than carotid CAS without cerebral protection?
The rationale for using a cerebral protection device is
that it catches any debris released during angioplasty and
stent deployment. Although stenting maintains laminar
flow across the stenosis and seals the site of dissection,
thereby preventing a free intimal flap, the wire mesh of the
stent may act as a ‘‘cheese grater’’ during deployment
because the stent shortens during expanding and may slice
debris off the atheromatous plaque into the cerebral
circulation.
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cerebral protection devices on the 30-day risks of stroke/
death.11,15 The use of protection devices was not allo-
cated randomly (e.g. 227 protection vs 20 no protection
in EVA-3S11; 151 protection vs 416 no protection in
SPACE15). This, therefore, introduces the possibility of se-
lection bias compromising any assessment of the effect of
protection devices. Furthermore, there was significant
heterogeneity between two trials in the results (chi
squared 4.53, PZ 0.03; I2Z 78%). When the results from
SPACE and EVA-3S were pooled, no significant difference
in the 30-day rate of death/stroke was observed in the
fixed-effect model (29/378 [7.7%] where protection was
used vs 33/436 [7.6%] where no protection was used;
OR: 0.77, 95% CI: 0.41e1.46). In the random-effects
model, the OR was 0.57, 95% CI: 0.14e2.33.
5. Is CAS as effective as CEA in reducing the 30-day risk of
stroke/death among patients with neurologically
asymptomatic carotid stenoses?
Only two trials have reported 30-day stroke/death rates
in neurologically asymptomatic patients16,19 and in one of
these19 there were no periprocedural strokes or deaths at
all. Accordingly, the test for heterogeneity is not applica-
ble. The overall results are therefore derived from the
CAVATAS trial16 and are extremely imprecise due to the
very small number of outcome events. The fixed-effect
model showed no significant difference in periprocedural
stroke or death among patients assigned carotid angio-
plasty/stent (3/30 [10%]) compared with endarterectomy
(2/21 [10%]). The fixed-effect and random-effects OR was
1.06 (95% CI: 0.16 to 6.94).Summary
The overall results of the systematic review and meta-
analysis suggest that CAS and CEA have similar perioper-
ative mortality rates (1.2%). The 30-day risk of ‘any
stroke’ is about 40% higher after CAS (95%CI 5e84%),
the absolute risk difference being 2% (30-day stroke rate
after CASZ 8% vs 6% after CEA). However, the safety
results for 30-day stroke among the various trials were
heterogeneous, probably because of the use of different
patients, revascularisation procedures and duration of
follow up. This degree of heterogeneity invokes doubt
as to whether the results obtained from a meta-analysis
of all studies are valid internally and externally. The
small number of outcome events recorded in the trials
limits statistical power to provide reliable overall esti-
mates of the safety and efficacy of CAS compared with
CEA. Finally, the very few long-term outcome events
(published to-date) make comparison of the long-term
efficacy of CAS with CEA (regarding stroke prevention)
quite uncertain.Implications for Practice
At present, CEA should remain the ‘‘gold standard’’
treatment for patients with a carotid stenosis and CASshould continue to be regarded as a research procedure
(just as CEA was considered before it was proven to be
effective in large randomised controlled trials1). Patients
with a carotid stenosis should be told that there are not
enough reliable data to form any valid conclusions about
CAS (compared with CEA), other than the significantly
lower rate of perioperative cranial neuropathy and the sim-
ilar perioperative death rate.
It remains uncertain whether CAS is effective in pre-
venting stroke in the long-term, whether it is acceptably
safe in minimising perioperative stroke (compared with
CEA) and whether there are any benefits afforded by the
extra costs associated with sophisticated delivery systems
(e.g. self expanding thermal stents) and protection de-
vices. There is also considerable uncertainty regarding
whether it is possible to reliably identify patients in
whom CAS (or CEA) is the preferred option or when neither
intervention is appropriate. A subgroup analysis from the
SPACE study suggests that older patients (>68 years) may
gain less benefit from CAS because of an increased pro-
cedural risk (10.8% vs 2.7%).23 This potentially important
observation requires corroboration in future studies. It
also reinforces the recommendation from the meta-analysis
of trials of CEA to consider surgery in older patients with
symptomatic carotid stenoses because the absolute bene-
fits of CEA are greater than is observed in younger
patients.1
The lack of reliable answers to the questions posed above
should encourage patients and clinicians to participate in
one or more of the ongoing randomised trials comparing CAS
with CEA (see below). Nevertheless, even this lack of reliable
evidence for the safety and efficacy of CAS compared with
CEA is unlikely to see stenting restricted to participation in
clinical trials. Already, emerging trends suggest an increas-
ing use of CAS around the world. The reasons for this include
an intuitive patient preference for undergoing a less invasive
procedure coupled with an increasing number of trained and
enthusiastic interventional radiologists, cardiologists and
vascular surgeons who are keen to increase their experience
with CAS. Similar trends have been observed in the manage-
ment of coronary stenosis, despite randomised trials favour-
ing coronary artery bypass grafting (CABG) surgery over
coronary stenting.Implications for Research
More individual patient data (from at least another 3,000
patients) entering randomised trials are required to add to
the existing systematic review and meta-analysis before we
can reliably conclude whether CAS is inferior to, non-
inferior to, or more effective than, CEA. These data should
be forthcoming from the ongoing International Carotid
Stenting Study (ICSS; http://www.cavatas.com), which is
recruiting patients with symptomatic carotid stenosis in
Europe, Canada and Australasia, and the Carotid Revascu-
larization Endarterectomy versus Stent Trial (CREST;
http://www.cresttrial.org), which is recruiting patients
with symptomatic and asymptomatic carotid stenosis in
North America. Safety data should be available from both
trials later in 2008, but evidence for long-term effective-
ness will require a few more years to accumulate.
40 Graeme J. HankeyTwo other large RCTs comparing stenting with endarter-
ectomy in neurologically asymptomatic patients have re-
cently commenced recruitment: the Asymptomatic Carotid
Surgery Trial-2 (ACST-2; http://www.acst.org.uk) and the
Carotid Stenting versus Surgery of Severe Carotid Artery Dis-
ease and Stroke Prevention in Asymptomatic Patients (ACT1;
http://www.act1trial.com). A third (SPACE II) has just se-
cured funding to enable recruitment from Germany, Austria
and Switzerland (Neurologie@med.uni-heidelberg.de),
while a fourth (TACIT) is still trying to obtain funding in
North America.
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